Marked efficacy of combined three‐drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome | Zendy

Morimoto M. | Zendy; Shimakawa S. | Zendy; Hashimoto T. | Zendy; Kitaoka T. | Zendy; Kyotani S. | Zendy

Premium

Marked efficacy of combined three‐drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome

Author(s) -

Morimoto M.,

Shimakawa S.,

Hashimoto T.,

Kitaoka T.,

Kyotani S.

Publication year - 2018

Publication title -

journal of clinical pharmacy and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.622

H-Index - 73

eISSN - 1365-2710

pISSN - 0269-4727

DOI - 10.1111/jcpt.12659

Subject(s) - dravet syndrome , topiramate , medicine , clobazam , anesthesia , antiepileptic drug , drug , valproic acid , anticonvulsant , pharmacology , pediatrics , epilepsy , psychiatry

Summary What is known and objective Dravet syndrome ( DS ) is an intractable epilepsy syndrome. The three‐drug combination therapy of sodium valproate ( VPA ), clobazam ( CLB ) and stiripentol ( STP ) is recommended worldwide. Case summary We present a case of DS , in which treatment with CLB could not be continued because of the appearance of adverse reactions to it. Replacement with topiramate ( TPM ) proved to be markedly effective. What is new and conclusion It is suggested that combination therapy with VPA , TPM and STP is for DS epilepsy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research